Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

ESR1 alterations and metastasis in estrogen receptor positive breast cancer.

Lei JT, Gou X, Seker S, Ellis MJ.

J Cancer Metastasis Treat. 2019;5. pii: 38. doi: 10.20517/2394-4722.2019.12. Epub 2019 May 4.

2.

Copy number alterations associated with clinical features in an underrepresented population with breast cancer.

Rodrigues-Peres RM, de S Carvalho B, Anurag M, Lei JT, Conz L, Gonçalves R, Cardoso Filho C, Ramalho S, de Paiva GR, Derchain SFM, Lopes-Cendes I, Ellis MJ, Sarian LO.

Mol Genet Genomic Med. 2019 Jul;7(7):e00750. doi: 10.1002/mgg3.750. Epub 2019 May 16.

3.

[Study on Ranunculaceae herbal decoction pieces using X-ray diffraction].

Lu DY, Kang S, Zhao YZ, Lei JT.

Zhongguo Zhong Yao Za Zhi. 2019 Feb;44(3):482-488. doi: 10.19540/j.cnki.cjcmm.20181129.005. Chinese.

PMID:
30989912
4.

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer.

Lei JT, Gou X, Ellis MJ.

Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. doi: 10.1080/23723556.2018.1526005. eCollection 2018.

5.

DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.

Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, Ellis MJ.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11978-E11987. doi: 10.1073/pnas.1810598115. Epub 2018 Nov 29.

6.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

7.

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.

Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE.

Oncogene. 2018 Aug;37(33):4581-4598. doi: 10.1038/s41388-018-0284-2. Epub 2018 May 11.

8.

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ.

Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.

9.

Proteogenomics connects somatic mutations to signalling in breast cancer.

Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; NCI CPTAC.

Nature. 2016 Jun 2;534(7605):55-62. doi: 10.1038/nature18003. Epub 2016 May 25.

10.

Three lysine residues in the common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling.

Lei JT, Mazumdar T, Martinez-Moczygemba M.

J Biol Chem. 2011 Nov 18;286(46):40091-103. doi: 10.1074/jbc.M111.273482. Epub 2011 Sep 30.

11.

Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.

Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, Lei JT, Moore JP, Tavana G, Lewis LR, Zhu Y, Muzny DM, Gibbs RA, Huston DP.

J Exp Med. 2008 Nov 24;205(12):2711-6. doi: 10.1084/jem.20080759. Epub 2008 Oct 27.

12.

Separate endocytic pathways regulate IL-5 receptor internalization and signaling.

Lei JT, Martinez-Moczygemba M.

J Leukoc Biol. 2008 Aug;84(2):499-509. doi: 10.1189/jlb.1207828. Epub 2008 May 29.

13.

N'-(3-Eth-oxy-2-hydroxy-benzyl-idene)-3-hydroxy-naphthalene-2-carbohydrazide.

Lei JT, Jiang YX, Tao LY, Huang SS, Zhang HL.

Acta Crystallogr Sect E Struct Rep Online. 2008 Apr 26;64(Pt 5):o909. doi: 10.1107/S1600536808010933.

14.

Bis{2-[2-(isopropyl-ammonio)ethyl-imino-meth-yl]-6-methoxy-phenolato}nickel(II) dithio-cyanate.

Ma HB, Jiang YX, Lei JT.

Acta Crystallogr Sect E Struct Rep Online. 2008 Mar 29;64(Pt 4):m597-8. doi: 10.1107/S1600536808008052.

15.

JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization.

Martinez-Moczygemba M, Huston DP, Lei JT.

J Leukoc Biol. 2007 Apr;81(4):1137-48. Epub 2007 Jan 16.

PMID:
17227823
16.

Editorial: The Whipple Riddle.

Lei JT.

JAMA. 1976 Mar 15;235(11):1148. No abstract available.

PMID:
55503

Supplemental Content

Support Center